The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Open accessAbstract
Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).Methods Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 weeks until unacceptable adverse events or disease progression. Investigators and patients were masked to assignment. The primary endpoint was progression-free survival (PFS) by independent central review, analysed by intention to treat after 714 events in all patients. The key secondary endpoint was overall survival, analysed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients. This trial is registered with ClinicalTrials.gov, number NCT00805194.Findings Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo. The primary analysis was done after a median follow-up of 7·1 months (IQR 3·8-11·0). PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3·4 months [95% CI 2·9-3·9] vs 2·7 months [2·6-2·8]; hazard ratio [HR] 0·79 [95% CI 0·68-0·92], p=0·0019). After a median follow-up of 31·7 months (IQR 27·8-36·1), overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10·9 months [95% CI 8·5-12·6] vs 7·9 months [6·7-9·1]; HR 0·75 [95% CI 0·60-0·92], p=0·0073). Similar results were noted for all patients with adenocarcinoma histology (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12·6 months [95% CI 10·6-15·1] vs 10·3 months [95% CI 8·6-12·2]; HR 0·83 [95% CI 0·70-0·99], p=0·0359), but not in the total study population (median 10·1 months [95% CI 8·8-11·2] vs 9·1 months [8·4-10·4]; HR 0·94, 95% CI 0·83-1·05, p=0·2720). Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6·6%] of 652 vs 17 [2·6%] of 655), reversible increases in alanine aminotransferase (51 [7·8%] vs six [0·9%]), and reversible increases in aspartate aminotransferase (22 [3·4%] vs three [0·5%]). 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).Interpretation Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, especially for patients with adenocarcinoma.Funding Boehringer Ingelheim.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with docetaxel, the combination of nintedanib and docetaxel was associated with a higher incidence of gastrointestinal AEs and transient elevation of liver enzymes [102].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Additional unplanned analyses revealed a pronounced impact on OS in patients with fast-progressing disease and patients who were refractory to first-line chemotherapy.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [102]
In the citing paper
“Unfortunately, survival outcomes remain poor and patients often experience substantial toxicity, underscoring a high unmet need. 8 , 9”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Research works printed but not linked: 2
- Hanna, 2013, Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled phase III trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy, Eur J Cancer, 49, 3418
- Reck, 2013, Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy, J Thorac Oncol, 8, O16.01
Cited by
Sorted by citations
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L. L. C., & Paz-Ares, L. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,430
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citationPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Phenotype molding of stromal cells in the lung tumor microenvironment
Lambrechts, D., Wauters, E., Boeckx, B., Aibar, S., Nittner, D., Burton, O., Bassez, A., Decaluwé, H., Pircher, A., Van den Eynde, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0096-5 · Cited by 1,648
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Self-citationExploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B. M., McGraw, T. E., & Mittal, V. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,170
Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T. S. K., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,162
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,074
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 998
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T. L., Elkin, S. K., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 818
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
Reck, M., & Rabe, K. F. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703413 · Cited by 739
Self-citationTargeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 685
Self-citationde Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Self-citationTargeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Zhao, Y., & Adjei, A. A. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0465 · Cited by 573
New and emerging targeted treatments in advanced non-small-cell lung cancer
Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 497
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 457
Gainor, J. F., Curigliano, G., Kim, D., Lee, K. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G. D. L., Jr., Tan, D. S. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00247-3 · Cited by 445
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yüzügülen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 416
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Möbitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 365
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Le, X., Nilsson, M. B., Goldman, J. W., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt‐Moller, B., Wolff, K., Visseren‐Grul, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 357
Self-citationNintedanib: From Discovery to the Clinic
Roth, G. J., Binder, R., Colbatzky, F., Dallinger, C., Schlenker‐Herceg, R., Hilberg, F., Wollin, S. L., & Kaiser, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501562a · Cited by 346
Self-citationRecent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 335
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Ballester, B., Milara, J., & Cortijo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030593 · Cited by 318
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J. R., Antonia, S. J., Mok, T. S. K., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 318
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Self-citationSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente‐Macías, Á., Baillache, D. J., Croke, S., & Unciti‐Broceta, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 294
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
Han, B., Li, K., Zhao, Y., Li, B., Cheng, Y., Zhou, J., Lü, Y., Shi, Y., Wang, Z., Jiang, L., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.478 · Cited by 258
Zhao, Y., Guo, S., Deng, J. M., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70958 · Cited by 265
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01544 · Cited by 244
Self-citationManegold, C., Dingemans, A. C., Gray, J. E., Nakagawa, K., Nicolson, M. C., Peters, S., Reck, M., Wu, Y.-L. L. C., Brustugun, O. T., Crinò, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.003 · Cited by 243
Self-citationAnti-Angiogenics: Current Situation and Future Perspectives
Zirlik, K., & Duyster, J. (2018) · Oncology Research and Treatment · doi:10.1159/000488087 · Cited by 218
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R. R. H., Ebner, T., Stopfer, P., & Dallinger, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00766-0 · Cited by 222
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Aebi, S. P., Gelber, S. I., Anderson, S., Láng, I., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Cañada, J. M. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70589-8 · Cited by 213
Squamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 215
du Bois, A., Kristensen, G. B., Ray-Coquard, I. L., Reuß, A., Pignata, S., Colombo, N., Denison, U., Vergote, I. B., Campo, J. M. D., Ottevanger, P. B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00366-6 · Cited by 210
Akl, M. R., Nagpal, P., Ayoub, N. M., Tai, B., Prabhu, S. A., Capac, C. M., Gliksman, M., Goy, A. H., & Suh, K. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8203 · Cited by 212
Lung cancer and interstitial lung disease: a literature review
Naccache, J., Gibiot, Q., Monnet, I., Antoine, M., Wislez, M., CHOUAID, C., & Cadranel, J. L. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.75 · Cited by 208
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 212
Chung, C. H., Guthrie, V. B., Masica, D. L., Tokheim, C. J., Kang, H., Richmon, J. D., Agrawal, N., Fakhry, C., Quon, H., Subramaniam, R. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv109 · Cited by 211
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., Franchina, T., Steen, N. V. D., van Dam, P. A., Ferri, J., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.018 · Cited by 201
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Pisarsky, L., Bill, R., Fagiani, E., Dimeloe, S., Goosen, R., Hagmann, J., Hess, C., & Christofori, G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.028 · Cited by 206
Minguet, J., Smith, K. H., & Bramlage, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 198
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Liu, G., Chen, T., Ding, Z., Wang, Y., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13009 · Cited by 196
Vimalraj, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.129 · Cited by 198
Shimizu, T., Sands, J. M., Yoh, K., Spira, A. I., Garon, E. B., Kitazono, S., Johnson, M. L., Meric‐Bernstam, F., Tolcher, A. W., Yamamoto, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00059 · Cited by 195
Camidge, D. R., Bar, J., Horinouchi, H., Goldman, J. W., Moiseenko, F. V., Filippova, E., Çiçin, İ., Ciuleanu, T., Daaboul, N., Liu, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00720 · Cited by 196
Kenmotsu, H., & Tanigawara, Y. (2015) · Cancer Science · doi:10.1111/cas.12647 · Cited by 177
Ambrogio, C., Goméz-López, G., Falcone, M., Vidal, A., Nadal, E., Crosetto, N., Blasco, R. B., Fernández-Marcos, P. J., Sánchez‐Céspedes, M., Ren, X., et al. (2016) · Nature Medicine · doi:10.1038/nm.4041 · Cited by 178
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem, M., Juan, Ó., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García‐Campelo, R., García, Y. G., Guirado, M., & Provencio, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1978-1 · Cited by 178
Lung cancer in patients with idiopathic pulmonary fibrosis
Karampitsakos, Τ., Tzilas, V., Tringidou, R., Steiropoulos, P., Aidinis, V., Papiris, S. A., Bouros, D. E., & Τzouvelekis, Α. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.016 · Cited by 173
Scagliotti, G. V., Gaafar, R. M., Nowak, A. K., Nakano, T., van Meerbeeck, J. P., Popat, S., Vogelzang, N. J., Grosso, F., Aboelhassan, R., Jakopović, M., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30139-0 · Cited by 168
Self-citationDy, G. K., Govindan, R., Velcheti, V., Falchook, G. S., Italiano, A., Wolf, J., Sacher, A. G., Takahashi, T., Ramalingam, S. S., Dooms, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02524 · Cited by 163
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis
Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160
Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective
Varricchi, G., Ameri, P., Dessalvi, C. C., Ghigo, A., Madonna, R., Marone, G., Mercurio, V., Monte, I. P., Novo, G., Parrella, P., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00167 · Cited by 167
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 159
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Deng, G. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i5.787 · Cited by 157
The Microenvironment of Lung Cancer and Therapeutic Implications
Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 154
Wu, S., & Fu, L. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0775-3 · Cited by 145
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
Grosso, F., Steele, N. L., Novello, S., Nowak, A. K., Popat, S., Greillier, L., John, T., Leighl, N. B., Reck, M., Taylor, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.9012 · Cited by 143
Self-citationImmunotherapy in NSCLC: A Promising and Revolutionary Weapon
Rolfo, C. D., Caglevic, C., Santarpía, M., Araújo, A., Giovannetti, E., Gallardo, C. D., Pauwels, P., & Mahave, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_5 · Cited by 145
Vessel co-option and resistance to anti-angiogenic therapy
Kuczynski, E. A., & Reynolds, A. R. (2019) · Angiogenesis · doi:10.1007/s10456-019-09698-6 · Cited by 138
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30561-7 · Cited by 133
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 134
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0044-2019 · Cited by 134
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L., & Knežević, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111102 · Cited by 134
Tocchetti, C. G., Dessalvi, C. C., Lisi, D. D., Femminò, S., Madonna, R., Mele, D., Monte, I. P., Novo, G., Penna, C. R. R., Pepe, A., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6930 · Cited by 132
Systemic treatment of brain metastases in non-small cell lung cancer
Page, S., Milner-Watts, C., Perna, M., Janžič, U., Vidal, N., Kaudeer, N., Ahmed, M., McDonald, F., Locke, I., Minchom, A. R., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.006 · Cited by 121
Myllärniemi, M., & Kaarteenaho, R. L. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26385 · Cited by 122
Targeting FGFR for cancer therapy
Zhang, P., Yue, L., Leng, Q., Chen, C., Gan, C., Ye, T., & Cao, D. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01558-1 · Cited by 130
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Nintedanib: First Global Approval
McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-014-0335-0 · Cited by 120
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
Arjaans, M., Schroder, C. P., Oosting, S. F., Dafni, U. G., Kleibeuker, J. E., & de Vries, E. G. E. (2016) · Oncotarget · doi:10.18632/oncotarget.6918 · Cited by 116
Reck, M., Taylor, F. C., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H. B., Orsini, L. S., & Gralla, R. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.029 · Cited by 111
Self-citationDeterminants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.09 · Cited by 110
Hilberg, F., Tontsch-Grunt, U., Baum, A., Le, A. T., Doebele, R. C., Lieb, S., Gianni, D., Voss, T., Garin‐Chesa, P., Haslinger, C., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244129 · Cited by 108
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 113
Conquering lung cancer: current status and prospects for the future
Pirker, R. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.02.005 · Cited by 101
Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics
Navarro, P., Bueno, M. J., Zagorac, I., Mondejar, T., Sanchez, J., Mourón, S., Muñoz, J., Gómez-López, G., Jimenez-Renard, V., Mulero, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.052 · Cited by 102
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens
Bubendorf, L., Lantuéjoul, S., de Langen, A. J., & Thunnissen, E. (2017) · European Respiratory Review · doi:10.1183/16000617.0007-2017 · Cited by 102
Angiogenesis Inhibitors in NSCLC
Manzo, A., Montanino, A., Carillio, G., Costanzo, R., Sandomenico, C., Normanno, N., Piccirillo, M. C., Daniele, G., Perrone, F., Rocco, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102021 · Cited by 104
Patients with IPF and lung cancer: diagnosis and management
Τzouvelekis, Α., Spagnolo, P., Bonella, F., Vancheri, C., Tzilas, V., Crestani, B., Kreuter, M., & Bouros, D. E. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30478-2 · Cited by 100
Tyrosine Kinase Receptors in Oncology
Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 104
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 105
Nokihara, H., Lü, S., Mok, T. S. K., Nakagawa, K., Yamamoto, N., Shi, Y., Zhang, L., Soo, R. A., Yang, J. C., Sugawara, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx419 · Cited by 97
Zhou, M., Chen, X., Zhang, H., Xia, L., Tong, X., Zou, L., Hao, R., Pan, J., Zhao, X. Q., Chen, D., et al. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0383-7 · Cited by 100
Totzeck, M., Mincu, R., Mrotzek, S. M., Schadendorf, D., & Rassaf, T. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318755193 · Cited by 100
Contribution of pericyte paracrine regulation of the endothelium to angiogenesis
Caporali, A., Martello, A., Miscianinov, V., Maselli, D., Vono, R., & Spinetti, G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.001 · Cited by 96
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 99
Friedlaender, A., Banna, G. L., Malapelle, U., Pisapia, P., & Addeo, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00166 · Cited by 93
Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 93
Metadata
- Authors
- Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., Gann, C.-N., Barrueco, J., Gaschler-Markefski, B., & Novello, S.
- Affiliations
- German Center for Lung Research (DE)
- Boehringer Ingelheim (Germany) (DE)
- Herlev Hospital (DK)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Meir Medical Center (IL)
- Dnipro State Medical University (UA)
- Shanghai Jiao Tong University (CN)
- Boehringer Ingelheim (United States) (US)
- University of Turin (IT)
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 15
- Issue
- 2
- Pages
- 143-155
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2170030318
- Cited by
- 951
- References
- 36
- Citations by year
- 2026: 35 · 2025: 41 · 2024: 64 · 2023: 67 · 2022: 74 · 2021: 67 · 2020: 72 · 2019: 83 · 2018: 81 · 2017: 117 · 2016: 103 · 2015: 102 · 2014: 45
- FWCI
- 98.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, docetaxel, nintedanib, second-line therapy, progression-free survival, overall survival, tyrosine kinase inhibitors, EGFR inhibitors, bevacizumab, brain metastases, adenocarcinoma, targeted therapy, combination chemotherapy, drug safety and tolerability
- MeSH terms
- Docetaxel, Adenocarcinoma of Lung, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Europe, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Risk Factors, South Africa, Time Factors, Proportional Hazards Models, Odds Ratio, Treatment Outcome, Disease Progression, Disease-Free Survival, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
